Table 3.
Summary of included studies: secondary characteristics
| Trial, year published | Onset to groin puncture (min) | CT to groin puncture (min) | Onset to randomization (min) | ASPECT median (interquartile range) |
NIHSS score, mean/median Post treatment |
|---|---|---|---|---|---|
| ESCAPE, 2015 9 | 24 h: | ||||
| IV | 172 (119–284) | 9 (8–10) | 13 (6–18) | ||
| EVT | 200 | 51 (39–68) | 169 (117–285) | 9 (8–10) | 6 (3–14) |
| EXTEND 1A, 2015 10 | Only given as reduction from baseline | ||||
| IV | |||||
| EVT | 210 (166–251) | 93 (71–138) | Not given | Not given | |
| IMS III, 2013 5 | Used for stratification for mRS; full data not presented | ||||
| IV | |||||
| EVT | 208 (SD 46·7) | N/A | N/A | Not given | |
| MR CLEAN, 2015 8 | 24 h: | ||||
| IV | 196 (149–266) | 9 (8–10) | 16 (12–21) | ||
| EVT | 260 (210–313) | Not given | 204 (152–251) | 9 (7–10) | 13 (6–20) |
| MR RESCUE, 2013 7 | |||||
| IV | |||||
| Penumbral | |||||
| Non‐penumbral | |||||
| EVT | 330 | N/A | N/A | Not given | Not given |
| Penumbral | |||||
| Non‐penumbral | |||||
| REVASCAT, 2015 11 | At 90 days: | ||||
| IV | 226 (168–308) | 8 (6–9) | 6·0 (2·0–11·0) | ||
| EVT | 269 (201–340) | N/A | 223 (170–312) | 7 (6–9) | 2·0 (0·0–8·0) |
| SWIFT PRIME, 2015 12 | At 27 h: | ||||
| IV | 9 (8–10) | −8·5 ± 7·1 | |||
| EVT | 224 | 58 (41–83) | N/A | 9 (7–10) | −3·9 ± 6·2 |
| SYNTHESIS, 2013 6 | Day 7 (or at discharge): | ||||
| IV | N/A | N/A | 145 (119–179) | 13 (9–18) | |
| EVT | N/A | N/A | 148 (124–190) | Not given | 13 (9–17) |